Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 4, 2010, Pages 548-554

  Nemec, Pavel ^a   Zemanova, Zuzana ^b   Greslikova, Henrieta ^a   Michalova, Kyra ^b   Filkova, Hana ^a   Tajtlova, Jana ^b   Kralova, Dana ^a   Kupska, Renata ^a   Smetana, Jan ^a   Krejci, Marta ^c   Pour, Ludek ^c   Zahradova, Lenka ^c   Sandecka, Viera ^c   Adam, Zdenek ^c   Buchler, Tomas ^d   Spicka, Ivan ^b   Gregora, Evzen ^e   Kuglik, Petr ^a   Hajek, Roman ^a,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

1q21 Gain; Chromosomal aberrations; Fluorescein in situ hybridization; Multiple myeloma; Survival

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; MELPHALAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME 4P; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 4; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERPHASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; CHROMOSOME 1; CHROMOSOME ABERRATION; COHORT ANALYSIS; GENETICS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 77949284411     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.025     Document Type: Article

References (39)

1. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
2. Moreau P., Hullin C., Garban F., et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 107 (2006) 397-403
3. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
4. San Miguel J.F., Schlag R., Khuageva N., et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood 110 (2007) Abstract 76
5. Cremer F.W., Bila J., Buck I., et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44 (2005) 194-203
6. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101 (2003) 4569-4575
7. Sawyer J.R., Waldron J.A., Jagannath S., and Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82 (1995) 41-49
8. Sawyer J.R., Tricot G., Mattox S., Jagannath S., and Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 91 (1998) 1732-1741
9. Sawyer J.R., Tricot G., Lukacs J.L., et al. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer 42 (2005) 95-106
10. Chang H., Qi X., Trieu Y., et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 135 (2006) 486-491
11. Hanamura I., Stewart J.P., Huang Y., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108 (2006) 1724-1732
12. Spruck C., Strohmaier H., Watson M., et al. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell 7 (2001) 639-650
13. Ganoth D., Bornstein G., Ko T.K., et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 3 (2001) 321-324
14. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10 (2005) 117-126
15. Inoue J., Otsuki T., Hirasawa A., et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 165 (2004) 71-81
16. Fonseca R., Harrington D., Oken M.M., et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group Study. Cancer Res 62 (2002) 715-720
17. Chang H., Qi C., Yi Q.L., Reece D., and Stewart A.K. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105 (2005) 358-360
18. Gutierrez N.C., Castellanos M.V., Martin M.L., et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21 (2007) 143-150
19. Avet-Loiseau H., Facon T., Grosbois B., et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99 (2002) 2185-2191
20. Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 109 (2007) 3489-3495
21. Hajek R., Spicka I., Scudla V., et al. Consolidation therapy based on conventional chemotherapy and corticoids do not provide therapeutic advantage for newly diagnosed patients after autologous transplantation. Blood 110 (2007) Abstract 531
22. Ahmann G.J., Jalal S.M., Juneau A.L., et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 101 (1998) 7-11
23. UCSC Genome Bioinformatics. Available at: http://genome.ucsc.edu/cgi-bin/hgGateway. Accessed November 20, 2007.
24. American Society of Medial Genetics: Standards and Guidelines for Clinical Genetics Laboratories. Available at: http://www.acmg.net/Pages/ACMG_Activities/stds-2002/e.htm. Accessed November 20, 2007.
25. Ross F.M., Avet-Loiseau H., Drach J., Hernandez Rivas J.M., and Liebisch P. European myeloma network recommendations for FISH in myeloma. Haematologica 92 (2007) Abstract 114
26. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
27. Seidl S., Kaufmann H., and Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 4 (2003) 557-564
28. Smadja N.V., Bastard C., Brigaudeau C., et al. Groupe Français de Cytogénétique Hématologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98 (2001) 2229-2238
29. Fonseca R., Van Wier S.A., Chng W.J., et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 20 (2006) 2034-2040
30. Qazilbash M.H., Saliba R.M., Ahmed B., et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13 (2007) 1066-1072
31. Chang H., Qi X., Jiang A., Xu W., Young T., and Reece D. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant (2009) [Epub ahead of print]
32. Shaughnessy Jr. J.D., Zhan F., Burington B.E., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109 (2007) 2276-2284
33. Richardson PG, Barlogie B, Berenson J, et al. http://www.ncbi.nlm.nih.gov/pubmed?term=%22Singhal%20S%22%5BAuthor%5D &itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstra ct Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005;106:2977-2981.
34. Jagannath S., Richardson P.G., Sonneveld P., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21 (2007) 151-157
35. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 (2008) 906-917
36. Reece D., Song K.W., Fu T., et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114 (2009) 522-525
37. Bahlis N.J., Song K., Trieu Y., et al. Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but not del17p13 in multiple myeloma: results of the Canadian MM016 Trial. Blood 110 (2007) Abstract 3597
38. Avet-Loiseau H., Soulier J., Fermand J.P., et al. Impact of chromosomal abnormalities Del(13), T(4;14), and Del(17p) and prior treatment on outcomes in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 112 (2008) Abstract 3685
39. Chang H., Trieu Y., Qi X., Xu W., Stewart K.A., and Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 31 (2007) 779-782